This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Positive Clinical And Technical Outcomes Of Asleep DBS With The ClearPoint System Recently Presented

IRVINE, Calif., Oct. 28, 2013 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB:MRIC) today announced that outcomes data from the use of its ClearPoint ® Neuro Intervention System in "asleep" deep brain stimulation (DBS) surgery were presented during the 2013 Annual Meeting of the Congress of Neurological Surgeons (CNS) in San Francisco.

In an Original Science Program talk entitled "Application Accuracy of a Second Generation Interventional MRI Stereotactic Platform: Initial Experience in 101 DBS Electrode Implantations," Dr. Paul Larson, neurosurgeon at the University of California, San Francisco (UCSF), presented accuracy results from a prospective study of 60 patients who underwent asleep DBS with the ClearPoint System at UCSF between August 2010 and March 2013. Highlights of the study included:
  • 98% of electrodes were placed with a single pass into the brain;
  • No electrodes have required repositioning;
  • The average accuracy of the electrode placement was 0.6 millimeter;
  • Average surgical times were 3 hours 4 minutes for bilateral cases and 2 hours 23 minutes for unilateral cases.

"Almost every electrode was placed with a single pass to the brain," Dr. Larson stated after his presentation, "meaning we hit the target the first time in each of those cases. More importantly, we hit the correct target based on the fact that no patients have returned for repositioning. We were able to do this through real-time image guidance enabled by ClearPoint."

During a reception sponsored by MRI Interventions on Monday, October 21, Dr. Fiona Gupta, neurologist at Hackensack University Medical Center (HUMC), presented clinical outcomes of asleep DBS with the ClearPoint System at HUMC. Dr. Gupta collected data regarding 11 patients, with an average post-operative follow-up of 15 months. Highlights from Dr. Gupta's presentation included:
  • Patients' motor symptom scores improved an average of 72% on the Unified Parkinson's Disease Rating Scale (UPDRS), when comparing their pre-operative "off medication" UPDRS scores to their post-operative "on medication" UPDRS scores;
  • Patients' post-operative Levodopa dosages decreased by an average of 71% from their pre-operative dosages.

"We've been very impressed with the outcomes we have seen so far," said Dr. Gupta. "My patients have had dramatic improvement in their movement scores. Many of these patients would not have had the awake surgery, so these results were made possible by iMRI asleep DBS."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.64 -0.11%
FB $118.57 0.84%
GOOG $698.21 0.75%
TSLA $241.80 0.43%
YHOO $36.53 -0.19%


Chart of I:DJI
DOW 17,891.16 +117.52 0.66%
S&P 500 2,081.43 +16.13 0.78%
NASDAQ 4,817.5940 +42.2360 0.88%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs